105 related articles for article (PubMed ID: 1286872)
1. Engineering antibodies for therapy.
Adair JR
Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872
[TBL] [Abstract][Full Text] [Related]
2. Antibody engineering for the development of therapeutic antibodies.
Kim SJ; Park Y; Hong HJ
Mol Cells; 2005 Aug; 20(1):17-29. PubMed ID: 16258237
[TBL] [Abstract][Full Text] [Related]
3. Unleashing the power of antibodies: Engineering for tomorrow's therapy.
Sagar ; Takhellambam M; Rattan A; Prajapati VK
Adv Protein Chem Struct Biol; 2024; 140():1-36. PubMed ID: 38762268
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic proteins.
Dimitrov DS
Methods Mol Biol; 2012; 899():1-26. PubMed ID: 22735943
[TBL] [Abstract][Full Text] [Related]
5. Antibody engineering.
Nat Biotechnol; 2023 Nov; 41(11):1520. PubMed ID: 37950001
[No Abstract] [Full Text] [Related]
6. Arginine cluster introduction on framework region in anti-lysozyme antibody improved association rate constant by changing conformational diversity of CDR loops.
Maeta S; Nakakido M; Matsuura H; Sakai N; Hirata K; Kuroda D; Fukunaga A; Tsumoto K
Protein Sci; 2023 Sep; 32(9):e4745. PubMed ID: 37550885
[TBL] [Abstract][Full Text] [Related]
7. The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.
Khatib SE; Salla M
Leuk Res Rep; 2022; 18():100335. PubMed ID: 35832747
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Shaw S; Bourne T; Meier C; Carrington B; Gelinas R; Henry A; Popplewell A; Adams R; Baker T; Rapecki S; Marshall D; Moore A; Neale H; Lawson A
MAbs; 2014; 6(3):774-82. PubMed ID: 24670876
[TBL] [Abstract][Full Text] [Related]
9. Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex.
Kiyoshi M; Caaveiro JM; Miura E; Nagatoishi S; Nakakido M; Soga S; Shirai H; Kawabata S; Tsumoto K
PLoS One; 2014; 9(1):e87099. PubMed ID: 24475232
[TBL] [Abstract][Full Text] [Related]
10. With or without sugar? (A)glycosylation of therapeutic antibodies.
Hristodorov D; Fischer R; Linden L
Mol Biotechnol; 2013 Jul; 54(3):1056-68. PubMed ID: 23097175
[TBL] [Abstract][Full Text] [Related]
11. Homology modelling and bivalent single-chain Fv construction of anti-HepG2 single-chain immunoglobulin Fv fragments from a phage display library.
Ni M; Yu B; Huang Y; Tang Z; Lei P; Shen X; Xin W; Zhu H; Shen G
J Biosci; 2008 Dec; 33(5):691-7. PubMed ID: 19179757
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic applications of monoclonal antibodies.
Berger M; Shankar V; Vafai A
Am J Med Sci; 2002 Jul; 324(1):14-30. PubMed ID: 12120821
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging.
Panousis C; Pietersz GA
Drugs Aging; 1999 Jul; 15(1):1-13. PubMed ID: 10459728
[TBL] [Abstract][Full Text] [Related]
14. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.
Ghetie MA; Podar EM; Ilgen A; Gordon BE; Uhr JW; Vitetta ES
Proc Natl Acad Sci U S A; 1997 Jul; 94(14):7509-14. PubMed ID: 9207122
[TBL] [Abstract][Full Text] [Related]
15. Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region.
Keck PC; Huston JS
Biophys J; 1996 Oct; 71(4):2002-11. PubMed ID: 8889174
[TBL] [Abstract][Full Text] [Related]
16. The biology and pathology of Fc receptors.
Sandor M; Lynch RG
J Clin Immunol; 1993 Jul; 13(4):237-46. PubMed ID: 8227284
[No Abstract] [Full Text] [Related]
17. Antibodies generated from human immunoglobulin miniloci in transgenic mice.
Wagner SD; Williams GT; Larson T; Neuberger MS; Kitamura D; Rajewsky K; Xian J; Brüggemann M
Nucleic Acids Res; 1994 Apr; 22(8):1389-93. PubMed ID: 8190629
[TBL] [Abstract][Full Text] [Related]
18. Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice.
Turner A; King DJ; Farnsworth AP; Rhind SK; Pedley RB; Boden J; Boden R; Millican TA; Millar K; Boyce B
Br J Cancer; 1994 Jul; 70(1):35-41. PubMed ID: 8018538
[TBL] [Abstract][Full Text] [Related]
19. Unaltered immunoglobulin expression in hybridoma cells modified by targeting of the heavy chain locus with an integration vector.
Mocikat R; Kardinal C; Lang P; Zeidler R; Thierfelder S
Immunology; 1995 Jan; 84(1):159-63. PubMed ID: 7890299
[TBL] [Abstract][Full Text] [Related]
20. Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves.
Taylor G; Thomas LH; Wyld SG; Furze J; Sopp P; Howard CJ
J Virol; 1995 Nov; 69(11):6658-64. PubMed ID: 7474075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
